Waregem (Belgium) / Rotterdam (the Netherlands)[1], 6 January 2014 – Arseus announces today that it has successfully completed the sale of its Dentals software Julie, Arseus Dental Lab, Arseus Dental Solutions Benelux and Arseus Dental Solutions France Ouest to Henry Schein (NASDAQ: HSIC) for a total cash consideration of € 50 million. Henry Schein is the world’s largest provider of health care products and services to office-based dental, animal health and medical practitioners, headquartered in Melville, N.Y., United States. Together the divested activities represent annual sales of approximately € 70 million and these activities are deconsolidated as of 1 January 2014.
As announced in the press release of 2 August 2013 the Board of Directors of Arseus started an analysis of strategic options, both inside and outside Arseus, for the Healthcare Solutions and Healthcare Specialties divisions. This deal marks an important step in completion of this process.
The Board of Directors expects more news to be announced regarding the remaining activities in Healthcare Solutions and Healthcare Specialties in the first semester of 2014.
Ger van Jeveren, CEO of Arseus: “We are convinced that the dental distribution, lab and software activities will contribute to the future growth and expansion of Henry Schein’s European dental presence. This transaction enables Arseus to continue to invest in its global roll out of the Fagron activities, to further develop Corilus and to focus on the successful execution of its innovation strategy to create concepts and solutions with substantial added value.”
Furthermore, the transaction regarding the sale of the French dental distribution activities in the regions Paris, Lille and Lyon to MS Distribution, as announced on 7 November 2013, has been closed.
[1] This press release was sent out by Arseus NV and Arseus BV.
In the event of any discrepancy between the Dutch translation and the original English version of this press release, the latter shall prevail.
Please open the link below for the press release: